Chronic Idiopathic Constipation Treatment Market Leading Player 2022-28
The global chronic idiopathic constipation (cic) treatment market size was estimated at USD 8.2Bn in 2021, growing at a CAGR of 7.2% during the forecast period 2022-2028. Constipation is a disorder in which stool frequency drops to three times per week and stool passage becomes difficult. Constipation is a frequent functional gastrointestinal condition that can have a negative impact on a patient's life. The occurrence of persistent constipation problems with really no well-defined underlying issue is referred to as chronic idiopathic constipation. Irregular bowel motions, firm stools, straining during defecation, a sense of partial evacuation, bloating, and stomach pain, are all signs of chronic idiopathic constipation. Laboratory studies, endoscopy, radiographic examinations, magnetic resonance imaging, and physiological testing are used to identify chronic idiopathic constipation. For persistent idiopathic constipation, there are presently just a few authorized therapeutic options.
View Detailed Report Description here https://precisionbusinessinsights.com/market-reports/global-chronic-idiopathic-constipation-treatment-market/
Growing clinical studies and pharmaceutical company approval
of drug candidates to meet unmet medical requirements of chronic idiopathic constipation
therapy is a significant driver fueling market expansion during the forecast
timeframe. For example, Shire plc obtained a new drug application from the US
Food and Drug Administration in March 2018 for its drug candidate SHP555
(prucalopride) for the treatment of persistent idiopathic constipation in
adults. Renexxion is also undertaking a phase 2 clinical study for Naronapride
(ATI-7505), which is being developed for the treatment of a wide range of
gastrointestinal diseases, including chronic idiopathic constipation. Ironwood
and Allergan's Linzess (linaclotide) were authorized by the FDA in 2017 for the
treatment of acute and chronic idiopathic constipation. Moreover, 50 percent of
chronic constipation patients are unsatisfied with their present therapy, owing
to ineffectiveness, highlighting the ongoing medical need for more effective
and safer therapeutic treatments. Alternative therapies, such as home
treatments and herbal medications, also including herbal laxatives, probiotic
foods, and so on, are likely to be key roadblocks to market expansion.
The global chronic idiopathic constipation treatment market is
segmented in terms of Distribution Channel, Drug, and Geography. In terms of
Drug, the market is categorized into Laxatives, Osmotic Products, Chloride
Channel Activators, and Others. The laxatives division is anticipated to expand
at a significant pace during the forecast timeframe. In terms of Distribution
Channel, the market is classified into Retail Pharmacies, Hospital Pharmacies,
and Online sales. The hospital pharmacies division is categorized into expand
at a substantial pace during the forecast timeframe.
The worldwide Chronic Idiopathic Constipation Treatment Market
is dominated by North America. Due to the rising incidence of chronic
idiopathic constipation amongst some of the senior population in the area, the
region is expected to occupy a major share of the global Chronic Idiopathic
Constipation Treatment Market throughout the forecast period. The high
incidence of constipation and rising health-care spending in Asia Pacific, on
the other hand, are projected to boost the Chronic Idiopathic Constipation
Market in the forecast timeframe.
Request
sample report https://precisionbusinessinsights.com/request-sample?product_id=17646
There are
several industry players working in the chronic idiopathic constipation treatment market, which include GlaxoSmithKline
Plc. (U.K.), Bayer AG (Germany), Allergan Plc. (Ireland), Ironwood
Pharmaceuticals, Inc. (U.S.), Astellas Pharma, Inc. (Japan), synergy
pharmaceuticals, Inc. (U.S.), Sanofi S.A. (France), and Pfizer, Inc. (U.S.) to
name a few.
About
Precision Business Insights:
We are a market research company that strives to provide the highest
quality market research insights. Our diverse market research experts are
enthusiastic about market research and therefore produce high-quality research
reports. We have over 500 clients with whom we have a good business partnership
and capacity to provide in-depth research analysis for more than 30 countries.
In addition to deliver more than 150 custom solutions, we already have accounts
with the top five medical device manufacturers.
Precision Business Insights offers a variety of cost-effective and
customized research services to meet particular research requirements. We are a
leading research service provider because of our extensive database built by
our experts and the services we provide.
Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1
866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/
| D U N S® Number: 85278174
Comments
Post a Comment